AI Article Synopsis
- A 47-year-old man with a long history of ulcerative colitis experienced sudden acute epigastric pain, leading to a medical examination that revealed eosinophilic gastroenteritis.
- After initial treatment with steroids proved ineffective, the patient was given vedolizumab, which successfully alleviated his symptoms and showed significant improvement in both conditions during follow-up examinations.
- The study suggests that vedolizumab, known for treating ulcerative colitis, may also be a viable treatment option for eosinophilic gastroenteritis due to the shared mechanism of targeting eosinophils.
Article Abstract
A 47-year-old man with over 10 years' duration of ulcerative colitis treated by 5-aminosalicylic acid and intermittent topical steroids complained of acute epigastric pain. Esophagogastroduodenoscopy revealed diffuse mucosal edema with patchy redness, multiple erosions and nodularity of the stomach. Bioptic examination revealed marked eosinophilic infiltration, confirming the diagnosis of eosinophilic gastroenteritis. Systemic steroid therapy was initiated, whereas his ulcerative colitis and eosinophilia recurred when tapering the steroid. Addition of azathioprine was ineffective, and we subsequently started vedolizumab for eosinophilic gastroenteritis and ulcerative colitis. The medication effectively improved his abdominal symptoms and esophagogastroduodenoscopy and ileocolonoscopy 1 year later revealed endoscopic improvement of both diseases with histologically decreased level of eosinophilic infiltration. Considering that eosinophils also express α4β7 integrins, vedolizumab can be a possible therapeutic candidate for eosinophilic gastroenteritis as well as ulcerative colitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5217/ir.2024.00013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!